Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 8 |
| List of Tables | 8 | 2 |
| List of Figures | 10 | 3 |
| Stem Cell Therapy Market in Asia-Pacific to 2018 - Introduction | 13 | 1 |
| Stem Cell Therapy Market in Asia-Pacific to 2018 - Overview | 14 | 7 |
| Introduction | 14 | 1 |
| Market Characterization and Forecasts - Overview | 15 | 1 |
| Revenue Forecasts | 15 | 1 |
| Cost of Therapy | 16 | 1 |
| Allogeneic and Autologous Share | 17 | 1 |
| Stem Cell Therapy Patient Pool | 18 | 1 |
| Drivers and Barriers | 19 | 1 |
| Drivers | 20 | 1 |
| Favorable Regulation and Strong Government Support, with a Focus on Country-Specific Research to Address Unmet Needs | 20 | 1 |
| Strong Pipeline With 77% of Molecules in Phase II and Phase I/II | 20 | 1 |
| Marketed Products for the Treatment of Diseases such as AMI, CABG, Crohn s Anal Fistula and Type 1 and 2 DM | 20 | 1 |
| Emergence of Public Research Laboratories and Hospitals | 20 | 1 |
| Barriers | 20 | 1 |
| Unknown Therapeutic Outcomes and Reproducibility Problems | 20 | 1 |
| Lack of Patient Awareness | 20 | 1 |
| Stem Cell Therapy Market in Asia-Pacific to 2018 - India | 21 | 13 |
| Introduction | 21 | 1 |
| Regulatory Landscape | 21 | 1 |
| Market Characterization and Forecasts - Overview | 22 | 1 |
| Revenue Forecasts | 22 | 1 |
| Cost of Therapy | 23 | 1 |
| Stem Cell Patient Pool | 23 | 1 |
| CABG Market Characterization and Forecasts | 24 | 1 |
| Introduction | 24 | 1 |
| Revenue Forecasts | 24 | 1 |
| Cost of Therapy | 25 | 1 |
| Stem Cell Patient Pool | 26 | 1 |
| Type 2 DM Market Characterization and Forecasts | 27 | 1 |
| Introduction | 27 | 1 |
| Revenue Forecasts | 28 | 1 |
| Cost of Therapy | 29 | 1 |
| Stem Cell Patient Pool | 30 | 1 |
| LSCT Market Characterization and Forecasts | 31 | 1 |
| Introduction | 31 | 1 |
| Revenue Forecasts | 31 | 1 |
| Cost of Therapy | 32 | 1 |
| Stem Cell Patient Pool | 33 | 1 |
| Stem Cell Therapy Market in Asia-Pacific to 2018 - China | 34 | 5 |
| Introduction | 34 | 1 |
| Regulatory Landscape | 34 | 1 |
| Market Characterization and Forecasts - Overview | 35 | 1 |
| Type 1 DM Market Characterization and Forecasts | 35 | 1 |
| Overview | 35 | 1 |
| Revenue Forecasts | 36 | 1 |
| Cost of Therapy | 37 | 1 |
| Stem Cell Patient Pool | 38 | 1 |
| Stem Cell Therapy Market in Asia-Pacific to 2018 - Japan | 39 | 6 |
| Introduction | 39 | 1 |
| Regulatory Landscape | 39 | 2 |
| Steroid Refractory aGvHD Market Characterization and Forecasts | 41 | 1 |
| Overview | 41 | 1 |
| Revenue Forecasts | 42 | 1 |
| Cost of Therapy | 43 | 1 |
| Stem Cell Patient Pool | 44 | 1 |
| Stem Cell Therapy Market in Asia-Pacific to 2018 - Singapore | 45 | 6 |
| Introduction | 45 | 1 |
| Regulatory Landscape | 45 | 1 |
| Ethical, Legal and Social Issues in Human Stem Cell Research, Reproductive and Therapeutic Cloning (June 2002) | 46 | 1 |
| Overview | 46 | 1 |
| Human Tissue Research (November 2002) | 47 | 1 |
| Overview | 47 | 1 |
| Research Involving Human Subjects (November 2004) | 48 | 1 |
| Overview | 48 | 1 |
| Genetic Testing and Genetic Research (November 2005) | 49 | 1 |
| Overview | 49 | 1 |
| Personal Information in Biomedical Research (May 2007) | 50 | 1 |
| Overview | 50 | 1 |
| Donation of Human Eggs for Research (November 2008) | 50 | 1 |
| Overview | 50 | 1 |
| Human-Animal Combinations in Stem Cell Research (September 2010) | 50 | 1 |
| Overview | 50 | 1 |
| Stem Cell Therapy Market in Asia-Pacific to 2018 - South Korea | 51 | 21 |
| Introduction | 51 | 1 |
| Regulatory Landscape | 51 | 2 |
| Market Characterization and Forecasts - Overview | 53 | 1 |
| Revenue Forecasts | 53 | 2 |
| Cost of Therapy | 55 | 1 |
| Stem Cell Patient Pool | 56 | 1 |
| Cupistem Market Characterization and Forecasts | 57 | 1 |
| Overview | 57 | 1 |
| Revenue Forecasts | 58 | 1 |
| Cost of Therapy | 59 | 1 |
| Stem Cell Patient Pool | 60 | 1 |
| HCG-AMI Market Characterization and Forecasts | 61 | 1 |
| Overview | 61 | 1 |
| Revenue Forecasts | 62 | 1 |
| Cost of Therapy | 63 | 1 |
| Stem Cell Patient Pool | 64 | 1 |
| Cartistem Market Characterization and Forecasts | 65 | 1 |
| Overview | 65 | 1 |
| Revenue Forecasts | 66 | 1 |
| Cost of Therapy | 67 | 1 |
| Stem Cell Patient Pool | 68 | 1 |
| CCG Market Characterization and Forecasts | 69 | 1 |
| Overview | 69 | 1 |
| Revenue Forecasts | 69 | 1 |
| Cost of Therapy | 70 | 1 |
| Stem Cell Patient Pool | 71 | 1 |
| Stem Cell Therapy Market in Asia-Pacific to 2018 - Pipeline Analysis | 72 | 19 |
| Pipeline Analysis by Phase | 72 | 1 |
| Pipeline Analysis by Sponsors/Collaborators | 73 | 1 |
| Pipeline Analysis by Country | 74 | 1 |
| India Stem Cell R&D Pipeline | 75 | 1 |
| Overview | 75 | 1 |
| Phase II/III | 76 | 1 |
| Phase II | 76 | 1 |
| Phase I/II | 76 | 1 |
| Unknown | 76 | 1 |
| China Stem Cell R&D Pipeline | 77 | 1 |
| Overview | 77 | 1 |
| Post-Market | 78 | 1 |
| Phase II | 78 | 1 |
| Phase I/II | 79 | 1 |
| Phase I | 79 | 1 |
| Clinical Pre-Test | 80 | 1 |
| Unknown | 80 | 1 |
| Japan Stem Cell R&D Pipeline | 81 | 1 |
| Overview | 81 | 1 |
| Phase III | 82 | 1 |
| Phase II/III | 82 | 1 |
| Phase II | 83 | 1 |
| Phase I/II | 84 | 1 |
| Phase I | 84 | 1 |
| Singapore Stem Cell R&D Pipeline | 85 | 1 |
| Overview | 85 | 1 |
| Phase I/II | 85 | 1 |
| South Korea Stem Cell R&D Pipeline | 86 | 1 |
| Overview | 86 | 1 |
| Phase III | 87 | 1 |
| Phase II/III | 87 | 1 |
| Phase II | 87 | 1 |
| Phase I/II | 87 | 1 |
| Phase I | 88 | 1 |
| Unknown | 88 | 1 |
| Product Profiles of Promising Molecules | 88 | 1 |
| JR-031 | 88 | 1 |
| CCG | 88 | 1 |
| Product Profiles of Marketed Products | 89 | 1 |
| HCG-AMI | 89 | 1 |
| Cartistem | 89 | 1 |
| CardioRel | 89 | 1 |
| Cupistem | 90 | 1 |
| ReliNethra | 90 | 1 |
| Stem Cell Therapy Market in Asia-Pacific to 2018 - Competitive Landscape | 91 | 10 |
| Stempeutics Research | 91 | 1 |
| Overview | 91 | 1 |
| Product Pipeline | 92 | 1 |
| Reliance Life Sciences | 93 | 1 |
| Overview | 93 | 1 |
| Product Pipeline | 93 | 1 |
| International Stem Cell Services | 94 | 1 |
| Overview | 94 | 1 |
| Product Pipeline | 94 | 1 |
| Shenzhen Beike Biotechnology | 95 | 1 |
| Overview | 95 | 1 |
| Product Pipeline | 95 | 1 |
| JCR Pharmaceuticals | 96 | 1 |
| Overview | 96 | 1 |
| Product Pipeline | 96 | 1 |
| ES Cells International (Subsidiary of BioTime, Inc) | 97 | 1 |
| Overview | 97 | 1 |
| Product Pipeline | 97 | 1 |
| Stem Cell Technologies i | 98 | 1 |
| Overview | 98 | 1 |
| Product Pipeline | 98 | 1 |
| Pharmicell | 99 | 1 |
| Overview | 99 | 1 |
| Product Pipeline | 99 | 1 |
| Medipost | 100 | 1 |
| Overview | 100 | 1 |
| Product Pipeline | 100 | 1 |
| Stem Cell Therapy Market in Asia-Pacific to 2018 - Strategic Consolidations | 101 | 4 |
| Overview | 101 | 1 |
| M&A Deals | 102 | 1 |
| RNL BIO Acquired 10% Stake in Celltex Therapeutics for $10m - October 28, 2011 | 102 | 1 |
| BioTime Acquired ES Cell International - May 3, 2010 | 102 | 1 |
| BCCL Acquires Stake in Life Cell - May 1, 2007 | 102 | 1 |
| Licensing Deals | 102 | 1 |
| RNL BIO Forms Joint Venture to Develop Stem Cell Therapy - September 29, 2011 | 102 | 1 |
| Kiadis Pharma Enters into Licensing Agreement with Hospira for ATIR - January 4, 2011 | 102 | 1 |
| Cipla Enters into Co-Marketing Agreement with Stempeutics - April 27, 2010 | 102 | 1 |
| Teijin Enters into Licensing Agreement with SanBio - March 2, 2010 | 102 | 1 |
| Cleveland BioLabs Enters into Licensing Agreement with Zhejiang Hisun Pharma - September 9, 2009 | 103 | 1 |
| Merck Signs a Licensing Agreement with Japan Tobacco - September 25, 2008 | 103 | 1 |
| ES Cell Enters into Licensing Agreement with ITI Life Sciences - January 31, 2007 | 103 | 1 |
| Co-Development Deals | 103 | 1 |
| JCR Pharma Enters into Co-Development Agreement with MediPal - September 13, 2011 | 103 | 1 |
| Athersys Enters into Co-Development Agreement with Pfizer - December 21, 2009 | 103 | 1 |
| Genzyme Enters into Agreement with Osiris Therapeutics - November 4, 2008 | 104 | 1 |
| JCR Pharma Enters into Co-Development Agreement with Mochida Pharma - December 21, 2007 | 104 | 1 |
| Stem Cell Therapy Market in Asia-Pacific to 2018 - Appendix | 105 | 8 |
| Market Definitions | 105 | 1 |
| Abbreviations | 105 | 2 |
| Bibliography | 107 | 1 |
| Research Methodology | 108 | 2 |
| Coverage | 108 | 1 |
| Secondary Research | 108 | 1 |
| Primary Research | 109 | 1 |
| Therapeutic Landscape | 109 | 3 |
| Epidemiology-based Forecasting | 109 | 2 |
| Market Size by Geography | 111 | 1 |
| Geographical Landscape | 112 | 1 |
| Pipeline Analysis | 112 | 1 |
| Competitive Landscape | 112 | 1 |
| Expert Panel Validation | 112 | 1 |
| Contact Us | 112 | 1 |
| Disclaimer | 112 | 1 |